Compare ADMA Biologics Inc (ADMA) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs UiPath Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while UiPath Inc trades at $11.38 (market cap $6.04B). The key difference: UiPath Inc is far larger — about 2.8× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | PATH | |
|---|---|---|
Market Cap | $2.13B | $6.04B |
Sector | Health | Technology |
52-Week High | $20.38 | $19.29 |
52-Week Low | $7.60 | $9.38 |
Enterprise Value | $2.20B | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UiPath (PATH) trades at $11.65, down 0.51% on the day, with a bullish technical signal driven by moving averages. The company shows improving fundamentals with revenue growth from $1.43B in 2025 to a projected $1.7B in 2026 and a shift to profitability. Recent news highlights expansion in agentic AI and enterprise automation, though the stock faces competitive and execution risks.
The outlook is cautiously optimistic with a consensus price target of $13.33 suggesting 14% upside. Key opportunities include strong revenue growth and margin expansion, while risks involve intense competition and the need to sustain AI-driven adoption. Analyst sentiment is mixed with 25% buy ratings amid ongoing transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
